NASDAQ:AURA Aura Biosciences (AURA) Stock Price, News & Analysis $5.89 -0.05 (-0.84%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.94 +0.05 (+0.85%) As of 05/23/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aura Biosciences Stock (NASDAQ:AURA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aura Biosciences alerts:Sign Up Key Stats Today's Range$5.75▼$5.9950-Day Range$4.90▼$7.5052-Week Range$4.35▼$12.38Volume158,183 shsAverage Volume210,758 shsMarket Capitalization$296.08 millionP/E RatioN/ADividend YieldN/APrice Target$22.75Consensus RatingBuy Company OverviewAura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Read More… Aura Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreAURA MarketRank™: Aura Biosciences scored higher than 53% of companies evaluated by MarketBeat, and ranked 434th out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingAura Biosciences has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAura Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Aura Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Aura Biosciences are expected to decrease in the coming year, from ($1.66) to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aura Biosciences is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aura Biosciences is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAura Biosciences has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.83% of the float of Aura Biosciences has been sold short.Short Interest Ratio / Days to CoverAura Biosciences has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Aura Biosciences has recently increased by 10.77%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAura Biosciences does not currently pay a dividend.Dividend GrowthAura Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.83% of the float of Aura Biosciences has been sold short.Short Interest Ratio / Days to CoverAura Biosciences has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Aura Biosciences has recently increased by 10.77%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.82 News SentimentAura Biosciences has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Aura Biosciences this week, compared to 2 articles on an average week.Search Interest3 people have searched for AURA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows3 people have added Aura Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Aura Biosciences insiders have bought 558.77% more of their company's stock than they have sold. Specifically, they have bought $343,000.00 in company stock and sold $52,067.00 in company stock.Percentage Held by InsidersOnly 5.40% of the stock of Aura Biosciences is held by insiders.Percentage Held by Institutions96.75% of the stock of Aura Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aura Biosciences' insider trading history. Receive AURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address AURA Stock News HeadlinesAura Biosciences, Inc. (NASDAQ:AURA) Director David Michael Johnson Acquires 20,000 SharesMay 21, 2025 | insidertrades.comAura Biosciences' (AURA) Market Outperform Rating Reiterated at JMP SecuritiesMay 25 at 2:53 AM | americanbankingnews.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. May 25, 2025 | Golden Portfolio (Ad)JMP maintains $19 target on Aura Biosciences stock after FDA insightsMay 24 at 10:01 PM | uk.investing.comAura Biosciences Raises $69.9 Million in Public OfferingMay 16, 2025 | tipranks.comAura Biosciences Names Anthony Gibney Chief Financial, Business OfficerMay 16, 2025 | marketwatch.comAura Biosciences Announces Pricing of Public Offering of Common Stock and WarrantsMay 15, 2025 | globenewswire.comAura Biosciences Announces Proposed Public Offering of Common Stock and WarrantsMay 15, 2025 | globenewswire.comSee More Headlines AURA Stock Analysis - Frequently Asked Questions How have AURA shares performed this year? Aura Biosciences' stock was trading at $8.22 at the beginning of 2025. Since then, AURA shares have decreased by 28.3% and is now trading at $5.89. View the best growth stocks for 2025 here. How were Aura Biosciences' earnings last quarter? Aura Biosciences, Inc. (NASDAQ:AURA) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by $0.08. When did Aura Biosciences IPO? Aura Biosciences (AURA) raised $81 million in an IPO on Friday, October 29th 2021. The company issued 5,400,000 shares at $14.00-$16.00 per share. Who are Aura Biosciences' major shareholders? Top institutional shareholders of Aura Biosciences include Long Focus Capital Management LLC (6.61%), Levin Capital Strategies L.P. (2.71%), Nantahala Capital Management LLC (2.52%) and Regency Capital Management Inc. DE (1.49%). Insiders that own company stock include Matrix Capital Management Comp, Los Pinos Elisabet De, Janet Jill Hopkins, Conor Kilroy, Julie B Feder, Amy Elazzouzi, Cadmus Rich and Rosch Mark De. View institutional ownership trends. How do I buy shares of Aura Biosciences? Shares of AURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aura Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aura Biosciences investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/15/2025Today5/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AURA CIK1501796 Webwww.aurabiosciences.com Phone617-500-8864FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$22.75 High Stock Price Target$25.00 Low Stock Price Target$19.00 Potential Upside/Downside+286.2%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-41.57% Return on Assets-36.43% Debt Debt-to-Equity RatioN/A Current Ratio12.47 Quick Ratio12.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.58 per share Price / Book1.29Miscellaneous Outstanding Shares50,269,000Free Float47,254,000Market Cap$296.08 million OptionableNot Optionable Beta0.43 10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:AURA) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.